Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2485950 | Journal of Pharmaceutical Sciences | 2012 | 17 Pages |
ABSTRACT:Methotrexate (MTX) has been used to treat rheumatoid arthritis at low doses and leukemia at high doses; however, this drug can produce severe side effects. Our hypothesis is that MTX side effects can be attenuated by directing the drug to the target cells (i.e., leukocytes) using (cyclo(1,12)PenPRGGSVLVTGC) peptide (cIBR). To test this hypothesis, MTX was conjugated to the N-terminus of cIBR peptide to give MTX–cIBR conjugate. MTX–cIBR (5.0 mg/kg) suppressed joint arthritis in adjuvant arthritis rats and prevented periarticular inflammation and bone resorption of the limb joints. In vitro, the toxicity of MTX–cIBR peptide against Molt-3 T cells was inhibited by anti-lymphocyte function-associated antigen-1 (LFA-1) antibody and cIBR peptide in a concentration-dependent manner, suggesting that the uptake of MTX–cIBR was partially mediated by LFA-1. Chemical stability studies indicated that MTX–cIBR was most stable at pH 6.0. The MTX portion of MTX–cIBR was unstable under acidic conditions, whereas the cIBR portion was unstable under basic conditions. In biological media, MTX–cIBR had short half lives in rat plasma (44 min) and homogenized rat heart tissue (38 min). This low plasma stability may contribute to the low in vivo efficacy of MTX–cIBR; therefore, there is a need to design a more stable conjugate to improve the in vivo efficacy. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association.